Skip to Content
Merck
  • Pharmacoepidemiological characterization of psychotropic drugs consumption using a latent class analysis.

Pharmacoepidemiological characterization of psychotropic drugs consumption using a latent class analysis.

International clinical psychopharmacology (2010-10-01)
Laura Wainstein, Caroline Victorri-Vigneau, Véronique Sébille, Jean-Benoît Hardouin, Fanny Feuillet, Jacques Pivette, Anicet Chaslerie, Pascale Jolliet
ABSTRACT

France has one of the highest recorded rates of psychotropic use of drugs compared with other European countries, especially for anxiolytics, hypnotics and antidepressants. The aim of this study was to characterize the use of three psychotropic drugs among the most prescribed in France (bromazepam, paroxetine, zolpidem) using reimbursement databases in real-life conditions. Individuals from a region affiliated to the French General Health Insurance Scheme, who had received at least two dispensings of bromazepam, paroxetine or zolpidem reimbursed between 1 January and 30 June 2008, were included. We used a latent class analysis to identify different subgroups of users for these three psychotropic drugs. A total of 40,644 patients were included for bromazepam, 36,264 for zolpidem and 31,235 for paroxetine. Using latent class analysis, four clinical subtypes of users of bromazepam and zolpidem were identified: nonproblematic users, at-risk users, users with a probable mental disorder and compulsive users. Three subgroups were identified for paroxetine that differed rather by the prescription patterns. Users of anxiolytics and hypnotics with at-risk behaviours represented a significant proportion in the studied population. This original method could be extended to other prescription databases to identify populations at risk of abuse or dependence to psychotropic drugs.

MATERIALS
Product Number
Brand
Product Description

Supelco
Bromazepam solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®